Cargando…
Anti-PD-1 Immunotherapy and Radiotherapy for Stage IV Intrahepatic Cholangiocarcinoma: A Case Report
Due to the unsatisfactory robustness of current predictive biomarkers in many cases, application of immunotherapy in advanced cancers with limited treatment options, such as stage IV intrahepatic cholangiocarcinoma (ICC), was quite common. Hence, strategies to enhance the therapeutic effect of immun...
Autores principales: | Liu, Ze-Long, Liu, Xin, Peng, Hong, Peng, Zhen-Wei, Long, Jian-Ting, Tang, Di, Peng, Sui, Bao, Yong, Kuang, Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485089/ https://www.ncbi.nlm.nih.gov/pubmed/32984358 http://dx.doi.org/10.3389/fmed.2020.00368 |
Ejemplares similares
-
12 MULTIFOCAL INTRAHEPATIC CHOLANGIOCARCINOMA: IMMUNOGENOMIC AND EPIGENOMIC HETEROGENEITIES INFLUENCE THE RESPONSES TO TARGETED THERAPY AND IMMUNOTHERAPY
por: Chen, Shu-Ling, et al.
Publicado: (2021) -
Significant response to anti-PD-1 based immunotherapy plus lenvatinib for recurrent intrahepatic cholangiocarcinoma with bone metastasis: A case report and literature review
por: Chen, Wei-xun, et al.
Publicado: (2019) -
Stereotactic radiotherapy for intrahepatic cholangiocarcinoma
por: Borakati, Aditya, et al.
Publicado: (2022) -
Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma
por: Peng, Hong, et al.
Publicado: (2016) -
The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma
por: Fiste, Oraianthi, et al.
Publicado: (2021)